Clinical Trial Personalizing Radiation Therapy Through a Novel Lung Function Imaging Modality

Yevgeniy (Jenia) Vinogradskiy, PhD

University of Colorado Cancer Center

Disclosures

• Nothing to disclose

NIH Funding Information

• Clinical Trial Personalizing Radiation Therapy Through a Novel Lung Function Imaging Modality
• NCI: PAR-14-166: Early Phase Clinical Trials in Imaging and Image-Guided Interventions (R01)
• PI: Yevgeniy Vinogradskiy
  Co-investigators
  • CU: Brian Kavanagh, Moyed Miften, Leah Schubert, Phillip Koo (radiology), Derek Linderman (pulmonology)
  • Beaumont Health System: Edward Castillo, Thomas Guerrero
  • UT Galveston (now Emory University): Richard Castillo
• Submission History: 8th percentile, first submission
4DCT-Ventilation

- 4DCT acquired for simulation (reduced time, cost, dose)
- Anatomical + Functional information
- Good spatial resolution

Functional radiotherapy with 4DCT-Ventilation

- Use patients 4DCT data to generate ventilation image
- Use 4DCT-ventilation image to generate functional avoidance plan
- Hypothesis: 4DCT-ventilation functional avoidance will lead to reduced rate of radiation pneumonitis
- Clinical trial to evaluate 4DCT-ventilation functional avoidance

Clinical Motivation/Significance

- Radiation pneumonitis is a major limitation in thoracic radiotherapy
Preliminary Data

- Validation of 4DCT-Ventilation
- Functional avoidance feasible without sacrificing target/OAR goals
- Dose-function better predictor of pneumonitis than dose alone

Relevant Prior Experience

- PhD topic in radiation pneumonitis/Clinical toxicity
- Collaboration with relevant research team
- Experience writing a clinical trial
- 2-3 papers on the topic

Specific Aims

Clinical trial to evaluate 4DCT-ventilation functional avoidance in clinical trial for lung cancer patients

Specific aim 1: Evaluate clinical toxicity of functional avoidance radiation therapy

Specific aim 2: Treatment assessment using imaging and functional biomarkers

Specific aim 3: Identify quantitative imaging biomarkers that predict for clinical toxicity:

Implicit aim: Open + Complete a clinical trial
Key Scientific Outcomes

• Trial successfully opened at CU, William Beaumont, Denver VA
• 92 patients consented in 2.5 years

Key Scientific Outcomes

• Trial met pneumonitis futility criteria and progressed to stage II of accrual
• How to practically implement functional avoidance
  • Who can benefit
  • Workflow/QA
  • Treatment planning

Key Questions

• What happens when primary trial physicist goes on vacation?
• Stability/variability of image generation technique?
• What other factors affect toxicity?

Castillo et al
Kipritidis et al
Future research directions

- What happens when primary trial physicist goes on vacation?
- Partner with vendor to produce a commercial grade image generation software
- Stability/variability of image generation technique?
- Improve image generation robustness
- What other factors affect toxicity?
- What does functional avoidance look like in the setting of chemoRT+IO

Grant Advice for AAPM Members

- Keep applying (my funding success 4/28 = 14%)
- Range of ideas are suitable for grant applications

Thank you

University of Colorado
Austin Faught PhD
Leah Schubert PhD
Bernard Jones PhD
Moyed Miften PhD
Laurie Gaspar MD
Chad Rusthoven MD
Brian Kavanagh MD, MPH

William Beaumont Hospital
Richard Castillo PhD

Emory University
Richard Castillo PhD

Funding: R01CA200817, K01CA181292